Yaron Golan
Sign in

Yaron Golan

Hong Kong, Hong Kong0

CEO/CTO @ LifeMap Sciences | GeneCards™ — genomics platform with 5M+ users | Licensing to Novartis, GSK, Amgen, Sanofi, Genentech | 2x founder, exited to public co. | Hands-on AI agents & data engineering

Technology and innovation executive with 20+ years building genomics platforms and leading scientific teams. Architect of the GeneCards Suite used by 5M+ researchers worldwide.

AI Fluency
Claude

Claude

My daily driver for coding, testing and deployment

G

Grok Bot

My operating partner for running my company

ChatGPT

ChatGPT

My strategic thought partner

Q&A

What kind of work energizes you?

Post·1mo ago

Solving user needs with technology. It's not about creating the most sophisticated technological solution—it's about providing your users with the simplest, easiest way to achieve their goals or solve their needs. That focus on what users actually need, to predict what they will find useful - that's what got 5 million researchers in academia and pharma to adopt GeneCards and use it as their daily driver.

What AI tools do you use the most?

Post·1mo ago

I use a combination of AI tools for strategy, operations, sales, customer support, development, testing and deployment - and also as a PA in my personal life. Today, it's mostly Grok Bot, Claude and Codex.

I also built our own proprietary harness for biomedical research based on our knowledge graph, which we use to demonstrate our products' capabilities and identify business opportuntiies.

Projects
G
GENIE
AI research harness for biomedical question answering
An AI research harness that answers plain-language questions by querying the GeneCards Knowledge Graph and live literature. Rather than relying on language-model memory, it grades every finding by evidence and cites sources so researchers can verify answers.
G
GeneCards Knowledge Graph
Map of human biology with 200M+ facts
Built a knowledge graph connecting genes, variants, diseases, symptoms, proteins, pathways, drugs, clinical trials and literature. Each fact carries its source and evidence strength, enabling both scientists and AI systems to trust and trace information.
L
LifeMap Discovery
Research database of embryonic development and stem cells
Built BioTime's research database focusing on embryonic development and stem cells. The work was published as a scientific contribution in PLoS ONE.
G
GeneCards Suite
Integrated knowledgebase of human genes and diseases
Turned an academic database from the Weizmann Institute into a self-sustaining commercial platform used by over 5 million researchers globally. Licensed by Novartis, Amgen, GSK, Sanofi and Genentech. Built from 190+ curated sources covering genes, diseases, pathways, variants, function and expression.
Experience
LifeMap Sciences, Inc.
Co-Founder & Chief Executive Officer; Chief Technology Officer (prior to 2016)
LifeMap Sciences, Inc.
May 2012 — Jan 2021 · Hong Kong, Israel, China
Created and commercialized TGex, a clinical genomics platform used for 100,000+ clinical cases. The platform helps clinical geneticists find disease-causing variants from sequenced exomes or genomes and produce clinical reports. Deployed in US cloud, in-country in China, and behind hospital firewalls for paediatric and rare-disease services at HKU/Queen Mary Hospital, Hong Kong Children's Hospital, Beijing Children's Hospital, Shanghai Children's Medical Center and others across Europe. Extended interpretation beyond the 2% of the genome covered by exomes to ~20%, adding structural and copy-number variants and non-coding regulatory regions. Made clinical cases fast and repeatable with exomes fully annotated in under five minutes and phenotype-driven ranking placing causal variants first. Built the Greater China go-to-market through partnerships with Shanyi, Illumina and direct hospital deployments. Led a joint bid with Accenture for the Hong Kong Genome Institute's genomic data platform.
Xennex, Inc.
Founder & Chief Technology Officer
Xennex, Inc.
Dec 2002 — May 2012 · Boston, Tel Aviv, Hong Kong
Founded and led Xennex, the technology company behind GeneCards, built on a scientific collaboration with the Weizmann Institute of Science (2003–2025). Built an Israel-based team of software engineers, curators and bioinformaticians. Designed and implemented GDPR and HIPAA programmes and security controls for patient data. Oversaw infrastructure security, access controls, backup and disaster recovery for multi-terabyte data environments. Built LifeMap Discovery (2011–2015), a research database of embryonic development and stem cells published in PLoS ONE. Turned GeneCards from an academic database into a self-sustaining commercial platform with enterprise licences from top-tier pharma and biotech, scientific-advertising business and usage-analytics system for pricing. Sold Xennex to LifeMap Sciences (then a BioTime subsidiary) in May 2012.
K
Vice President, Research & Development
Koala Technologies, Ltd.
Jul 2006 — Nov 2007 · Israel
Led R&D for Tournamino, an early online prediction-market platform built around real-world event outcomes. The model was later popularized by Polymarket and Kalshi.
Valor Computerized Systems, Inc.
Project Manager; Vice President R&D, e4eNet subsidiary
Valor Computerized Systems, Inc.
Jul 1999 — Sep 2004 · Israel, Hong Kong
Worked on enterprise engineering and manufacturing software for the global electronics industry. Led the e4eNet B2B collaboration venture, whose technology and team were acquired by IBM in 2002. Created a patented part-management solution for electronics manufacturing by translating Fortune 500 customer requirements into product specifications. Conceived and built an innovative electronics-manufacturing collaboration platform with a 30-person team of developers, IT and customer-support engineers. Invented the security scheme allowing competing manufacturers to share design data safely and led the effort to make an open exchange standard the industry norm. Designed and led a 30-person-year mission-critical hardware and software electronics-intelligence system.
Education
Hong Kong University of Science and Technology - School of Business and Management
Hong Kong University of Science and Technology - School of Business and Management
Master of Business Administration (MBA) in Entrepreneurship/Entrepreneurial Studies
Sep 2011 — Jun 2011
The Open University of Israel
The Open University of Israel
Bachelor's Degree in Computer and Information Sciences, General
Sep 2009 — Jun 2009
S
School of Computers, IDF
Graduate in Computer Programming
Sep 1995 — Jun 1995
Ben Zvi
Ben Zvi
Credentials
G
Publication
Genome analysis and knowledge-driven variant interpretation with TGex
We present TGex, the Translational Genomics expert, a novel genome variation analysis and interpretation platform, with remarkable exome analysis capacities and a pioneering approach of non-coding variants interpretation. TGex’s main strength is combining state-of-the-art variant filtering with knowledge-driven analysis made possible by VarElect, our highly effective gene-phenotype interpretation tool. VarElect leverages the widely used GeneCards knowledgebase, which integrates information from > 150 automatically-mined data sources. Access to such a comprehensive data compendium also facilitates TGex’s broad variant annotation, supporting evidence exploration, and decision making. TGex has an interactive, user-friendly, and easy adaptive interface, ACMG compliance, and an automated reporting system. Beyond comprehensive whole exome sequence capabilities, TGex encompasses innovative non-coding variants interpretation, towards the goal of maximal exploitation of whole genome sequence analyses in the clinical genetics practice. This is enabled by GeneCards’ recently developed GeneHancer, a novel integrative and fully annotated database of human enhancers and promoters. Examining use-cases from a variety of TGex users world-wide, we demonstrate its high diagnostic yields (42% for single exome and 50% for trios in 1500 rare genetic disease cases) and critical actionable genetic findings. The platform’s support for integration with EHR and LIMS through dedicated APIs facilitates automated retrieval of patient data for TGex’s customizable reporting engine, establishing a rapid and cost-effective workflow for an entire range of clinical genetic testing, including rare disorders, cancer predisposition, tumor biopsies and health screening.
G
Publication
GeneAnalytics: An Integrative Gene Set Analysis Tool for Next Generation Sequencing, RNAseq and Microarray Data.
Postgenomics data are produced in large volumes by life sciences and clinical applications of novel omics diagnostics and therapeutics for precision medicine. To move from "data-to-knowledge-to-innovation," a crucial missing step in the current era is, however, our limited understanding of biological and clinical contexts associated with data. Prominent among the emerging remedies to this challenge are the gene set enrichment tools. This study reports on GeneAnalytics™ ( geneanalytics.genecards.org ), a comprehensive and easy-to-apply gene set analysis tool for rapid contextualization of expression patterns and functional signatures embedded in the postgenomics Big Data domains, such as Next Generation Sequencing (NGS), RNAseq, and microarray experiments. GeneAnalytics' differentiating features include in-depth evidence-based scoring algorithms, an intuitive user interface and proprietary unified data. GeneAnalytics employs the LifeMap Science's GeneCards Knowledgebase. Expression-based analysis in GeneAnalytics relies on the LifeMap Discovery®-the embryonic development and stem cells database, which includes manually curated expression data for normal and diseased tissues, enabling advanced matching algorithm for gene-tissue association. This assists in evaluating differentiation protocols and discovering biomarkers for tissues and cells. Results are directly linked to gene, disease, or cell "cards" in the GeneCards suite. Future developments aim to enhance the GeneAnalytics algorithm as well as visualizations, employing varied graphical display items. Such attributes make GeneAnalytics a broadly applicable postgenomics data analyses and interpretation tool for translation of data to knowledge-based innovation in various Big Data fields such as precision medicine, ecogenomics, nutrigenomics, pharmacogenomics, vaccinomics, and others yet to emerge on the postgenomics horizon.
L
Publication
LifeMap Discovery™: the embryonic development, stem cells, and regenerative medicine research portal
LifeMap Discovery™ provides investigators with an integrated database of embryonic development, stem cell biology and regenerative medicine. The hand-curated reconstruction of cell ontology with stem cell biology; including molecular, cellular, anatomical and disease-related information, provides efficient and easy-to-use, searchable research tools. The database collates in vivo and in vitro gene expression and guides translation from in vitro data to the clinical utility, and thus can be utilized as a powerful tool for research and discovery in stem cell biology, developmental biology, disease mechanisms and therapeutic discovery. LifeMap Discovery is freely available to academic nonprofit institutions at http://discovery.lifemapsc.com.
M
Publication
MalaCards: an integrated compendium for diseases and their annotation
Comprehensive disease classification, integration and annotation are crucial for biomedical discovery. At present, disease compilation is incomplete, heterogeneous and often lacking systematic inquiry mechanisms. We introduce MalaCards, an integrated database of human maladies and their annotations, modeled on the architecture and strategy of the GeneCards database of human genes. MalaCards mines and merges 44 data sources to generate a computerized card for each of 16 919 human diseases. Each MalaCard contains disease-specific prioritized annotations, as well as inter-disease connections, empowered by the GeneCards relational database, its searches and GeneDecks set analyses. First, we generate a disease list from 15 ranked sources, using disease-name unification heuristics. Next, we use four schemes to populate MalaCards sections: (i) directly interrogating disease resources, to establish integrated disease names, synonyms, summaries, drugs/therapeutics, clinical features, genetic tests and anatomical context; (ii) searching GeneCards for related publications, and for associated genes with corresponding relevance scores; (iii) analyzing disease-associated gene sets in GeneDecks to yield affiliated pathways, phenotypes, compounds and GO terms, sorted by a composite relevance score and presented with GeneCards links; and (iv) searching within MalaCards itself, e.g. for additional related diseases and anatomical context. The latter forms the basis for the construction of a disease network, based on shared MalaCards annotations, embodying associations based on etiology, clinical features and clinical conditions. This broadly disposed network has a power-law degree distribution, suggesting that this might be an inherent property of such networks. Work in progress includes hierarchical malady classification, ontological mapping and disease set analyses, striving to make MalaCards an even more effective tool for biomedical research. Database URL:http://www.malacards.org/
Recommendations
No recommendations yet
Nothing posted yet.
Skills
Data EngineeringSoftware as a Service (SaaS)Executive ManagementArtificial Intelligence (AI).NET CoreASP.NET CoreSoftware Project ManagementApplication DevelopmentProduct InnovationBusiness StrategyInformation TechnologyJavaScriptTeam LeadershipHTMLAgile MethodologiesSoftware Development
Unlock human wisdom
ThesisTermsPrivacy
© 2026 Saywise Inc.